THEATRE EFFICIENCIES
equipment from well-known brands, such as Maquet, ensuring the best possible care is provided. Whether dealing with crisis management, renovation work, or catering for a surge in demand, Getinge can help overcome these challenges. Capacity by Getinge includes:
l Individual flexibility
The solution is planned and designed with cost transparency according to individual needs and requirements in terms of cost- effectiveness, capacity and standards.
l Customised complete equipment Units are equipped with high-quality devices from trusted brands such as Getinge, Maquet or Arjo. The materials used for the construction and furnishings come from sustainable sources, are non-hazardous to health and support a healthy indoor climate.
l Rapid installation After a short construction time, the tailored solution will be delivered ready for use. Getinge manages the delivery, construction and set-up.
l Maximum standardisation The use of available space has been optimised to help maintain Trusts’ standardised processes.
l Avoiding unnecessary costs During construction or renovation work, CSSDs, theatres and ICUs can continue to operate unimpeded, outside of the building site, avoiding service provision interruption. The construction period can therefore be shortened and costs that arise from renovations being undertaken during ongoing operation (such as additional hygiene measures) can be avoided.
In conclusion, we are in the midst of unprecedented times and NHS Trusts and the MedTech industry must work together to overcome the elective surgery backlog challenges being faced. This article provides an insight into two key solutions to support the NHS in this area by improving efficiency and optimising the use of operating theatres with effective management systems, and also by increasing hospital capacity in short deployment cycles.
References 1
https://www.bbc.com/news/health-56752599 2
https://www.bbc.com/news/health-57092797, 18.05.21
3
https://www.birmingham.ac.uk/news/ latest/2020/05/covid-disruption-28-million-
surgeries-cancelled.aspx, 18.05.21
4
https://www.nhsconfed.org/resources/2021/03/ Building-back-elective-care
About the author CSJ
Tim Bryant is the commercial director and acting general manager at Getinge UK & Ireland, responsible for the commercial and strategic direction, growth and performance of Getinge UK&I. He is a skilled healthcare leader with over 18 years’ experience in the healthcare industry working in sales, marketing and strategy. Tim is known for developing and driving Getinge’s Flexible Commercial Solutions, a flexible strategic partnership to improve NHS efficiencies and productivities, while minimising financial and operational risks.
Want to identify what's in your sample....? Introducing Maldi-Tof bacterial identification:
Rapid & accurate identification of bacterial
species; enabling a faster, correct treatment of patients.
Reduces downtime for equipment. Informed decision making and risk assessment aided by accurate trending data.
Rapid identification of microorganisms can lead to a reduction in time to appropriate therapy, improve patient outcomes and potentially decrease the length of hospital stays and associated costs this incurs.
REDUCES: Turnaround time on Legionella
positives by 48 hours & 24 hours for
E.Coli/Coliforms & Psuedomonas positives
For more information, please contact:
Marianne: 07740819586
sales@2030lab.com or visit us on
www.2030lab.com/identifications
AUGUST 2021
WWW.CLINICALSERVICESJOURNAL.COM l 77
Did You Know? We can now identify over
10,000 species of bacteria
Microorganism identification
Subtyping
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88
